EEG and behavioral effects in animals of some amphetamine derivatives with hallucinogenic properties.

[1]  J. Duhault [Pharmacology and biochemistry of fenfluramine]. , 1973, La Vie medicale au Canada francais.

[2]  H. Himwich,et al.  Electroencephalographic analyses of amphetamine and its methoxy derivatives with reference to their sites of EEG alerting in the rabbit brain. , 1969, International journal of neuropharmacology.

[3]  A. Scotti de Carolis,et al.  EEG and behavioral effects of 2-5-methoxy-4-methyl-amphetamine (DOM, STP). , 1969, Archives internationales de pharmacodynamie et de therapie.

[4]  E. Uyeno Alteration of a learned response of the squirrel monkey by hallucinogens. , 1969, International journal of neuropharmacology.

[5]  A. Shulgin,et al.  Structure–Activity Relationships of One-Ring Psychotomimetics , 1969, Nature.

[6]  J. Mandel,et al.  A San Francisco Bay Area "speed" scene. , 1968, Journal of health and social behavior.

[7]  E. John,et al.  Observation Learning in Cats , 1968, Science.

[8]  S. Snyder,et al.  2,5-Dimethoxy-4-methyl-amphetamine (STP): A New Hallucinogenic Drug , 1967, Science.

[9]  L. C. Clark,et al.  Some New Behaviour-disrupting Amphetamines and their Significance , 1967, Nature.

[10]  M. R. Mickey,et al.  The effects of mescaline, amphetamine and four-ring substituted amphetamine derivatives on spontaneous brain electrical activity in the cat. , 1967, International Journal of Neuropharmacology.

[11]  J. Massingill,et al.  Two new alkaloids in cacti. , 1967, Tetrahedron letters.

[12]  A. Shulgin Possible Implication of Myristicin as a Psychotropic Substance , 1966, Nature.

[13]  Soulairac Ml Etiopathohenesis of testicular lesions in the Klinefelter syndrome with positive sex chromatin , 1963 .

[14]  L. Speck Electroencephalographic changes in the rat with mescaline intoxication. , 1958, The Journal of pharmacology and experimental therapeutics.

[15]  L. Speck Toxicity and effects of increasing doses of mescaline. , 1957, Journal of Pharmacology and Experimental Therapeutics.